Nektar Therapeutics (NKTR) Goodwill & Intangibles (2010 - 2022)
Nektar Therapeutics (NKTR) posted quarterly Goodwill & Intangibles of $76.5 million for Q4 2022, little changed year-over-year from $76.5 million in Q4 2021, and little changed quarter-over-quarter from $76.5 million in Q3 2022.
Analysis
Nektar Therapeutics (NKTR) Goodwill & Intangibles (2010 - 2022) Analysis & Trends
Nektar Therapeutics' Goodwill & Intangibles history runs 13 years deep, the most recent figure standing at $76.5 million for Q4 2022.
- In Q4 2022, Goodwill & Intangibles changed 0.0% year-over-year to $76.5 million; the TTM figure through Dec 2022 stood at $76.5 million (changed 0.0% YoY), while the FY2022 annual figure was $76.5 million, changed 0.0% from the prior year.
- Goodwill & Intangibles for Q4 2022 stood at $76.5 million, roughly flat from $76.5 million in the prior quarter.
- The five-year high for Goodwill & Intangibles was $76.5 million in Q1 2018, with the low at $76.5 million in Q1 2018.
- The 5-year median for Goodwill & Intangibles is $76.5 million (2018), against an average of $76.5 million.
- Peak annual rise in Goodwill & Intangibles reached 0.0% in 2018, while the deepest fall reached 0.0% in 2018.
- Nektar Therapeutics' Goodwill & Intangibles stood at $76.5 million in 2018, then changed by 0.0% to $76.5 million in 2019, then changed by 0.0% to $76.5 million in 2020, then changed by 0.0% to $76.5 million in 2021, then changed by 0.0% to $76.5 million in 2022.
- Business Quant data shows NKTR's Goodwill & Intangibles at $76.5 million in Q4 2022, $76.5 million in Q3 2022, and $76.5 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 76.50 Mn |
| Sep 30, 2022 | 76.50 Mn |
| Jun 30, 2022 | 76.50 Mn |
| Mar 31, 2022 | 76.50 Mn |
| Dec 31, 2021 | 76.50 Mn |
| Sep 30, 2021 | 76.50 Mn |
| Jun 30, 2021 | 76.50 Mn |
| Mar 31, 2021 | 76.50 Mn |
| Dec 31, 2020 | 76.50 Mn |
| Sep 30, 2020 | 76.50 Mn |
| Jun 30, 2020 | 76.50 Mn |
| Mar 31, 2020 | 76.50 Mn |
| Dec 31, 2019 | 76.50 Mn |
| Sep 30, 2019 | 76.50 Mn |
| Jun 30, 2019 | 76.50 Mn |
| Mar 31, 2019 | 76.50 Mn |
| Dec 31, 2018 | 76.50 Mn |
| Sep 30, 2018 | 76.50 Mn |
| Jun 30, 2018 | 76.50 Mn |
| Mar 31, 2018 | 76.50 Mn |